Parenteral Iron Therapy in the Pediatric Patient: A Review

ICAN: Infant, Child, & Adolescent Nutrition

Volumn 3, Issue 3, 2011, Pages 145-151

  Gura, Kathleen ^a   Chang, Esther ^a   Casey, Ashley ^b   Roach, Erin ^c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c University of North Carolina   (United States)

Author keywords

ferric gluconate; ferumoxytol; iron dextran; iron sucrose; iron deficiency anemia

Indexed keywords

EID: 84997941710     PISSN: 19414064     EISSN: None     Source Type: Journal    
DOI: 10.1177/1941406411408600     Document Type: Article

References (52)

1. Clark SF Iron deficiency anemia. Nutr Clin Pract. 2008;23: 128-141.
2. Centers for Disease Control and Prevention. Iron deficiency-United States, 1999-2000. MMWR Morb Mortal Wkly Rep. 2002; 51: 897-899.
3. Akman M., Cebeci D., Okur V., Angin H., Abali O., Akman AC The effects of iron deficiency on infants' developmental test performance. Acta Paediatr. 2004; 93: 1391-1396.
4. Lozoff B., Smith JB, Clark KM, Perales CG, Rivera F., Castillo M. Home intervention improves cognitive and social-emotional scores in iron-deficient anemic infants. Pediatrics. 2010;126: e884-e894.
5. McCann JC, Ames BN An overview of evidence for a causal relationship between iron deficiency during development and deficits in cognitive or behavioral function. Am J Clin Nutr. 2007; 85: 931-945.
6. Friel JK, Andrews WL, Hall MS, et al. Intravenous iron administration to very-low-birth-weight newborns receiving total and partial parenteral nutrition. JPEN J Parenter Enteral Nutr. 1995; 19: 114-118.
7. Zlotkin SH, Lay DM, Kjarsgaard J., Longley T. Determination of iron absorption using erythrocyte iron incorporation of two stable isotopes of iron (57Fe and 58Fe) in very low birthweight premature infants. J Pediatr Gastroenterol Nutr. 1995;21: 190-199.
8. Auerbach M., Rodgers GM Intravenous iron. N Engl J Med. 2007; 357: 93-94.
9. Watson Pharma, Inc. INFeD® (iron dextran) injection prescribing information. Morristown, NJ; September 2009.
10. American Regent, Inc. Dexferrum® (iron dextran) injection prescribing information. Shirley, NY; April 2010.
11. Foulkes WD, Sewry C., Calam J., Hodgson HJ Rhabdomyolysis after intramuscular iron-dextran in malabsorption. Ann Rheum Dis. 1991; 51: 184-186.
12. Mamula P., Piccoli DA, Peck SN, Markowitz JE, Baldassano RN Total dose intravenous infusion of iron dextran for iron-deficiency anemia in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2002; 34: 286-290.
13. Halpin TC Jr, Bertino JS, Rothstein FC, Kurczynski EM, Reed MD Iron-deficiency anemia in childhood inflammatory bowel disease: treatment with intravenous iron-dextran. JPEN J Parenter Enteral Nutr. 1982; 6: 9-11.
14. Auerbach M., Witt D., Toler W., Fierstein M., Lerner RG, Ballard H. Clinical use of the total dose intravenous infusion of iron dextran. J Lab Clin Med. 1988; 111: 566-570.
15. Monaghan MS, Glasco G., St John G., Bradsher RW, Olsen KM Safe administration of iron dextran to a patient who reacted to the test dose. South Med J. 1994; 87: 1010-1012.
16. Novey HS, Pahl M., Haydik I., Vaziri ND Immunologic studies of anaphylaxis to iron dextran in patients on renal dialysis. Ann Allergy. 1994; 72: 224-228.
17. Fishbane S., Kowalski EA The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate. Semin Dial. 2000; 13: 381-384.
18. Ganguli A., Kohli HS, Jha V., Gupta KL, Sakhuja V. The comparative safety of various intravenous iron preparations in chronic kidney disease patients. Ren Fail. 2008; 30: 629-638.
19. McCarthy JT, Regnier CE, Loebertmann CL, Bergstralh EJ Adverse events in chronic hemodialysis patients receiving intravenous iron dextran-a comparison of two products. Am J Nephrol. 2000; 20: 455-462.
20. Barton JC, Barton EH, Bertoli LF, Gothard CH, Sherrer JS Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation. Am J Med. 2000; 109: 27-32.
21. Chertow GM, Mason PD, Vaage-Nilsen O., Ahlmùn J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant. 2006; 21: 378-382.
22. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Important drug warning for Dexferrum® (iron dextran injection, USP).
23. Coyne DW, Adkinson NF, Nissenson AR, et al. Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. Kidney Int. 2003; 63: 217-224.
24. Van Wyck DB, Danielson BG, Aronoff GR Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial. Am J Kidney Dis. 2000; 36: 88-97.
25. Greenbaum LA, Pan CG, Caley C., Nelson T., Sheth KJ Intravenous iron dextran and erythropoietin use in pediatric hemodialysis patients. Pediatr Nephrol. 2000; 14: 908-911.
26. Warady BA, Kausz A., Lerner G., et al. Iron therapy in the pediatric hemodialysis population. Pediatr Nephrol. 2004; 19: 655-661.
27. Sanofi-Aventis, Ferrlicit (sodium ferric gluconate complex in sucrose injection prescribing information, Bridgewater, NJ; 2010.
28. Chertow GM, Mason PD, Vaage-Nilsen O., Ahlmùn J. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant. 2004; 19: 1571-1575.
29. Bailie GR, Clark JA, Lane CE, Lane PL Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant. 2005; 20: 1443-1449.
30. Silverstein SB, Rodgers GM Parenteral iron therapy options. Am J Hematol. 2004; 76: 74-78.
31. Warady BA, Zobrist RH, Wu J., Finan E.; Ferrlecit Pediatric Study Group. Sodium ferric gluconate complex therapy in anemic children on hemodialysis. Pediatr Nephrol. 2005; 20: 1320-1327.
32. Yorgin PD, Belson A., Sarwal M., Alexander SR Sodium ferric gluconate therapy in renal transplant and renal failure patients. Pediatr Nephrol. 2000; 15: 171-175.
33. Gillespie RS, Symons JM Sodium ferric gluconate for post-transplant anemia in pediatric and young adult renal transplant recipients. Pediatr Transplant. 2005; 9: 43-46.
34. Yee J., Besarab A. Iron sucrose: the oldest iron therapy becomes new. Am J Kidney Dis. 2002; 40: 1111-1121.
35. American Regent Inc. Venofer® (iron sucrose) injection prescribing information. Shirley, NY; 2008.
36. Pinsk V., Levy J., Moser A., Yerushalmi B., Kapelushnik J. Efficacy and safety of intravenous iron sucrose therapy in a group of children with iron deficiency anemia. Isr Med Assoc J. 2008; 10: 335-338.
37. Leijn E., Monnens LA, Cornelissen EA Intravenous iron supplementation in children on hemodialysis. J Nephrol. 2004; 17: 423-426.
38. Anbu AT, Kemp T., O'Donnell K., Smith PA, Bradbury MG Low incidence of adverse events following 90-minute and 3-minute infusions of intravenous iron sucrose in children on erythropoietin. Acta Paediatr. 2005; 94: 1738-1741.
39. Michaud L., Guimber D., Mention K., et al. Tolerance and efficacy of intravenous iron saccharate for iron deficiency anemia in children and adolescents receiving long-term parenteral nutrition. Clin Nutr. 2002; 21; 403-407.
40. AMAG Pharmaceuticals. Feraheme® (ferumoxytol) injection prescribing information. Lexington, MA; 2009.
41. Balakrishnan VS, Rao M., Kausz AT, et al. Physicochemical properties of ferumoxytol, a new intravenous iron preparation. Eur J Clin Invest. 2009; 39: 489-496.
42. Spinowitz BS, Kausz AT, Baptista J., et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol. 2008; 19: 1599-1605.
43. National Institutes of Health. Clinical Trials. gov.
44. Wan KK, Tsallas G. Dilute iron dextran formulation for addition to parenteral nutrient solutions. Am J Hosp Pharm. 1980; 37: 206-210.
45. Mayhew SL, Quick MW Compatibility of iron dextran with neonatal parenteral nutrient solutions. Am J Health Syst Pharm. 1997; 54: 570-571.
46. Reed MD, Bertino JS Jr, Halpin TC Jr. Use of intravenous iron dextran injection in children receiving total parenteral nutrition. Am J Dis Child. 1981; 135: 829-831.
47. MacKay M., Rusho W., Jackson D., McMillin G., Winther B. Physical and chemical stability of iron sucrose in parenteral nutrition. Nutr Clin Pract. 2009; 24: 733-737.
48. Aronoff GR Safety of intravenous iron in clinical practice: implications for anemia management protocols. J Am Soc Nephrol. 2004; 15(suppl 2):S99-S106.
49. Parkkinen J., von Bonsdorff L., Peltonen S., Grönhagen-Riska C., Rosenlöf K. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant. 2000; 15: 1827-1834.
50. Barry DM, Reeve AW Increased incidence of gram-negative neonatal sepsis with intramuscular iron administration. Pediatrics. 1977; 60: 908-912.
51. Hoen B., Paul-Dauphin A., Kessler M. Intravenous iron administration does not significantly increase the risk of bacteremia in chronic hemodialysis patients. Clin Nephrol. 2002; 57: 457-461.
52. Aronoff GR, Bennett WM, Blumenthal S., et al; United States Iron Sucrose (Venofer) Clinical Trials Group. Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens. Kidney Int. 2004; 66: 1193-1198.